<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJFNS</journal-id><journal-title-group><journal-title>Hans Journal of Food and Nutrition Science</journal-title></journal-title-group><issn pub-type="epub">2166-613X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJFNS.2018.72010</article-id><article-id pub-id-type="publisher-id">HJFNS-24925</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJFNS20180200000_14698034.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  母乳糖成分对新生儿肠道微生物的调节作用研究
  Review on the Regulation Function of Human Milk Glycans on Neonatal Gut Microbiota
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>雨奇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>尧</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>利龙</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>翘楚</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>金</surname><given-names>祺</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>露丹</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>明</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>大连医科大学基础医学院微生态学教研室，辽宁 大连</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>13234080178@163.com(胡雨)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>05</month><year>2018</year></pub-date><volume>07</volume><issue>02</issue><fpage>81</fpage><lpage>90</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   母乳中的糖成分在新生儿肠道微生物结构的建立和肠道内稳态的形成中发挥了至关重要的作用。大量研究表明，除为新生儿提供生长发育所需的营养和能量外，母乳中的多种糖成分可通过抑制病原菌粘附、促进肠道益生菌的定植和生长、减轻炎症反应等过程防止肠道感染，保护新生儿健康。本文就母乳中的主要糖成分对新生儿肠道微生物的调节作用作一综述。 The glycans in human milk play a vital role in the development of neonatal gut microbiota and the establishment of intestinal stability. A large number of studies have shown that in addition to provide nutrients and energy for newborns’ growth and development, a variety of glycans in human milk can inhibit the adhesion of pathogens, promote intestinal colonization and growth of probiotics, reduce inflammation and so on. Therefore, such processes can prevent intestinal infection and protect the health of newborns. This article reviews the regulation function of major components of glycans in breast milk on neonatal gut microbiota. 
  
 
</p></abstract><kwd-group><kwd>母乳，新生儿，肠道微生物，低聚糖，糖蛋白, Human Milk</kwd><kwd> Newborns</kwd><kwd> Gut Microbiota</kwd><kwd>Oligosaccharide</kwd><kwd> Glycoproteins</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>母乳糖成分对新生儿肠道微生物的调节作用研究<sup> </sup></title><p>胡雨奇，许尧，张利龙，刘翘楚，金祺，孙露丹，李明<sup>*</sup></p><p>大连医科大学基础医学院微生态学教研室，辽宁 大连</p><disp-formula id="hanspub.24925-formula39"><graphic xlink:href="//html.hanspub.org/file/3-1740249x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年4月24日；录用日期：2018年5月10日；发布日期：2018年5月17日</p><disp-formula id="hanspub.24925-formula40"><graphic xlink:href="//html.hanspub.org/file/3-1740249x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>母乳中的糖成分在新生儿肠道微生物结构的建立和肠道内稳态的形成中发挥了至关重要的作用。大量研究表明，除为新生儿提供生长发育所需的营养和能量外，母乳中的多种糖成分可通过抑制病原菌粘附、促进肠道益生菌的定植和生长、减轻炎症反应等过程防止肠道感染，保护新生儿健康。本文就母乳中的主要糖成分对新生儿肠道微生物的调节作用作一综述。</p><p>关键词 :母乳，新生儿，肠道微生物，低聚糖，糖蛋白</p><disp-formula id="hanspub.24925-formula41"><graphic xlink:href="//html.hanspub.org/file/3-1740249x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1740249x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1740249x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>人类肠道中含有10<sup>14</sup>个微生物，种类为500~3000种，细胞总数至少是人体细胞数量的10倍，基因组数量超过人类细胞核基因组100倍以上 [<xref ref-type="bibr" rid="hanspub.24925-ref1">1</xref>] 。微生物在新生儿肠道中的定植开始于母亲分娩时期，经历了从需氧菌定植到厌氧菌定植，菌群从单一到多样的演替过程 [<xref ref-type="bibr" rid="hanspub.24925-ref2">2</xref>] 。研究表明，分娩方式、喂养方式、母乳低聚糖分泌型、生活环境、益生元和抗生素的使用等多种因素影响着新生儿肠道菌群的形成和发展 [<xref ref-type="bibr" rid="hanspub.24925-ref3">3</xref>] ，肠道微生物逐渐成熟对营养吸收、物质代谢、生命早期免疫系统的形成和神经系统的发育等方面至关重要 [<xref ref-type="bibr" rid="hanspub.24925-ref4">4</xref>] ，而异常微生物的定居将长期影响宿主代谢和免疫系统的正常发育，引起多种疾病的发生发展。</p><p>母乳作为新生儿最早摄入的食物，主要由大量营养素(蛋白质，非蛋白含氮化合物，脂肪，乳糖)、微量营养素(维生素A，B1，B2，B6，B12，D和碘)、生物活性物质(生长因子，免疫因子)、益生菌等组成。在提供营养物质、促进机体生长和发育，防御病原菌感染、减轻炎症反应、促进婴儿免疫系统成熟等诸多方面发挥至关重要的作用 [<xref ref-type="bibr" rid="hanspub.24925-ref5">5</xref>] 。近年来，以低聚糖为代表的母乳中糖成分对肠道微生物的调节作用逐渐明确，母乳喂养的重要性不容置喙。</p><p>本文就母乳中低聚糖、葡萄糖胺聚糖、糖蛋白等主要糖成分对新生儿肠道微生物的建立、成熟和新生儿健康的影响展开综述，旨在为改善婴儿配方奶粉的成分和预防及治疗临床疾病提供理论依据。</p></sec><sec id="s4"><title>2. 母乳糖成分对新生儿肠道微生物的影响</title><p>母乳中的糖成分较为丰富，其主要成分为乳糖和低聚糖，其他类型的糖包括单糖、葡萄糖胺聚糖、糖蛋白和糖脂等 [<xref ref-type="bibr" rid="hanspub.24925-ref6">6</xref>] 。它们的浓度在不同个体和同一个体哺乳期的不同阶段均有所不同。母乳中的糖成分起到了抑制病原体粘附于肠黏膜、减轻炎症反应、直接刺激互利共生菌的生长等广泛作用 [<xref ref-type="bibr" rid="hanspub.24925-ref7">7</xref>] 。</p><sec id="s4_1"><title>2.1. 低聚糖</title><p>母乳低聚糖(Human milk oligosaccharides，HMOs)由5种单体组成：D-葡萄糖(D-glucose, Glc)、D-半乳糖(D-galactose, Gal)、N-乙酰氨基葡萄糖(N-acetylglucosamine, GlcNAc)、L-岩藻糖(L-fucose, Fuc)和唾液酸(sialic acid, Sia)。HMOs在核心结构的基础上可分为岩藻糖基化的中性HMOs(如2’-FL, 3FL)，唾液酸化的酸性HMOs(如3SL, 6SL)和非岩藻糖基化的中性HMOs (如LNT、LNnT、LNH) [<xref ref-type="bibr" rid="hanspub.24925-ref8">8</xref>] 。HMOs具有丰富的营养价值和重要的生物活性，能够促进正常肠道菌群的形成和婴儿免疫系统的发育，因而有助于防止病原菌定植并且降低感染风险 [<xref ref-type="bibr" rid="hanspub.24925-ref9">9</xref>] 。</p><p>近年来，国内外对HMOs研究较多，结合国内外文献，笔者对低聚糖的作用总结见图1。</p><p>图1. 母乳HMOs代谢转归及生物学功能 [<xref ref-type="bibr" rid="hanspub.24925-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.24925-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.24925-ref17">17</xref>]</p><sec id="s4_1_1"><title>2.1.1. 益生元作用</title><p>益生元是一种由肠道有益菌选择性代谢并可专一性改变有益菌组成和活性的不被消化的食物配料。母乳中的益生元如HMOs被称为“双歧因子”，由于其特殊的糖苷键组成，无法被消化道的胃酸和酶消化，可直达大肠被双歧杆菌、乳酸杆菌等肠道益生菌选择性利用，从而促进益生菌的增殖，影响肠道微生物的组成 [<xref ref-type="bibr" rid="hanspub.24925-ref10">10</xref>] 。细菌消化益生元释放糖，糖酵解产生短链脂肪酸，一方面除进一步促进双歧杆菌、乳酸杆菌的生长外，也有利于维持肠道上皮屏障功能的完整性；另一方面，短链脂肪酸使肠道内PH降低，形成酸性环境，对致病菌的生长起抑制作用。如Yu Zhuoteng等 [<xref ref-type="bibr" rid="hanspub.24925-ref11">11</xref>] 发现长双歧杆菌JCM7007和婴儿双歧杆菌ATCC15697能够消耗低聚糖产生的乳糖和短链脂肪酸，使肠道PH下降，从而抑制大肠杆菌和产气荚膜杆菌的生长。随着基因测序技术的发展，研究人员逐渐发现双歧杆菌对HMOs中具体成分的利用具有菌株特异性，如Takahiro M等 [<xref ref-type="bibr" rid="hanspub.24925-ref12">12</xref>] 首次提出FL转运蛋白ABC是婴幼儿肠道内双歧杆菌的关键定植因子，原因是FL转运蛋白可引起肠道微生物的变化和代谢物的产生。而在Daniel Garrido等 [<xref ref-type="bibr" rid="hanspub.24925-ref13">13</xref>] 针对长双歧杆菌B. longum SC596的研究中进一步证实，B. longum可优先利用岩藻糖基化的中性HMO (如2’-FL, LNFP)，B. infantis可同时消耗各种类型的HMOs，而B. breve则在优先利用SL后再利用非岩藻糖基化的中性HMOs。这表明在婴儿肠道中存在互补策略，即不同的益生菌种和亚种可以专一性利用HMOs不同组分，从而使HMOs的所有成分均可在结肠内被充分利用。因此，在开发针对婴儿肠道微生物的益生元时，婴儿肠道内双歧杆菌的表型和基因型特性应该予以考虑。</p></sec><sec id="s4_1_2"><title>2.1.2. 抑制病原菌粘附，影响免疫应答</title><p>HMOs可以阻断病原体与宿主细胞表面受体的结合，并改变外周血单核细胞、肠上皮细胞等多种细胞的免疫应答 [<xref ref-type="bibr" rid="hanspub.24925-ref14">14</xref>] 。肠道病原体与肠上皮细胞表面的特异性聚糖成分结合是其发病机制中的首要步骤。宿主细胞表达特异性聚糖表位的能力决定了每种病原体的器官和物种特异性。当该表位是可溶性聚糖的一部分时，可以竞争性抑制病原体与其受体结合的能力，从而使靶细胞免于感染。而HMOs中含有此类表位，保护母乳喂养的婴儿免受肠道病原体的感染 [<xref ref-type="bibr" rid="hanspub.24925-ref15">15</xref>] 。如Ruizpalacios G M等 [<xref ref-type="bibr" rid="hanspub.24925-ref16">16</xref>] 发现母乳低聚糖在小鼠体内和人小肠黏膜上均可抑制弯曲杆菌的定植，从而有助于抑制婴儿腹泻的发生。然而最近的一项研究发现，2’-FL可降低大肠杆菌F18对新生猪肠上皮细胞的粘附，却无法阻止F18导致的腹泻，显示出HMOs对免疫受损的新生儿肠道保护作用有限，引发了人们对HMOs可能在年龄、饮食和剂量等方面具有高度依赖性的猜测和进一步验证 [<xref ref-type="bibr" rid="hanspub.24925-ref17">17</xref>] 。</p></sec><sec id="s4_1_3"><title>2.1.3. 抑制炎症反应</title><p>N Nanda N等 [<xref ref-type="bibr" rid="hanspub.24925-ref18">18</xref>] 发现，2’-FL可以阻断肠黏膜中的炎症信号，有助于新生儿肠道菌群早期定植。在抑制坏死性小肠结肠炎(Necrotising enterocolitis, NEC)的发病中，既往研究已经证实二唾液酸乳-N-四糖(disialyllacto-N-tetraose，DSLNT)对大鼠NEC起到预防作用。Autran C A等 [<xref ref-type="bibr" rid="hanspub.24925-ref19">19</xref>] 最新临床实验显示，在患有NEC的早产婴儿中，其母亲母乳中的DSLNT浓度显著降低，表明母乳中的DSLNT水平可作为鉴别婴儿是否具有患NEC风险的可能指标。目前，研究人员对婴儿肠道内是否含有NEC标志性微生物观点不一，部分学者认为患有NEC婴儿的肠道内葡萄球菌、γ-变形菌纲等丰度增加并具有统计学意义，但更多的实验显示，与健康对照相比NEC婴儿肠道内微生物无显著性差异。但相比患有NEC的婴儿，健康婴儿肠道内微生物的多样性和稳定性增加，双歧杆菌丰度增加是普遍认同的观点。此外，最新研究发现，NEC婴儿肠道微生物改变将影响宿主代谢功能，如使亚油酸脂代谢产物发生变化，从而有望通过检测这些代谢产物来提前预测和诊断NEC的发病 [<xref ref-type="bibr" rid="hanspub.24925-ref20">20</xref>] 。当前已有研究证明2’-FL, SL可以起到缓解NEC的作用 [<xref ref-type="bibr" rid="hanspub.24925-ref21">21</xref>] ，但这种作用是否由肠道微生物介导需要研究人员的进一步验证。</p></sec><sec id="s4_1_4"><title>2.1.4. 平衡肠道微生物，促进机体正常发育</title><p>大量研究证明，HMOs可以通过抑制肠道有害菌生长、促进有益菌相互作用的方式平衡肠道微生物，进而促进新生儿的正常发育。Lin A E等 [<xref ref-type="bibr" rid="hanspub.24925-ref9">9</xref>] 证明，非唾液酸化的母乳低聚糖可与常规抗生素协同作用，直接抑制引起新生儿侵袭性感染的无乳链球菌的生长。Faust K等 [<xref ref-type="bibr" rid="hanspub.24925-ref22">22</xref>] 通过对粪便微生物群落的研究发现，肠道细菌不同物种之间的相互作用使得细菌群落比单个细菌更有效地利用物质。Mezoff E A等 [<xref ref-type="bibr" rid="hanspub.24925-ref23">23</xref>] 证明，在回盲肠切除术后，2’-FL可以通过增加体重、调节微生物群落多样性提高能量可用性，通过肠组织学变化增加肠道的适应性，从而降低短肠综合征的发生率。Charbonneau M R等 [<xref ref-type="bibr" rid="hanspub.24925-ref24">24</xref>] 发现，在血型为非分泌型的母乳中，与健康婴儿母乳相比，营养不良婴儿的母乳HMOs水平显著下降(P = 0.0013, t = 3.392)；而当用添加唾液酸化牛乳低聚糖(S-BMO)的食物喂养接种了营养不良婴儿微生物种群的小鼠后，小鼠体重、肌肉量、骨质密度指标增加，肝脏、肌肉和大脑代谢得以改善，机体发育趋于正常，而用同样食物喂养无菌小鼠，不出现上述改变。该研究提出，母乳中的唾液酸化低聚糖作为肠道内某些菌群生长所必须的促进因子，通过“交互共生”(crossfeed)作用影响其他菌群的生长，从而增加宿主对食物营养成分的利用效率，并可能导致主要代谢器官中代谢状态的改变。由此可以推测，母乳中低聚糖成分可能成为改善早产婴儿发育不良的新方法。</p></sec></sec><sec id="s4_2"><title>2.2. 葡萄糖胺聚糖</title><p>葡萄糖胺聚糖 (Glycosaminoglycans, GAGs) 是一种由可变数量的重复二糖单位组成的线性杂多糖，在母乳中以蛋白聚糖的形式存在并被婴儿摄取。根据化学组成可分为四类：透明质酸(hyaluronic acid, HA)、硫酸软骨素或硫酸皮肤素(galactosaminoglycans, chondroitin and dermatan sulfate, CS and DS)、肝素或硫酸乙酰肝素(the glucosaminoglycans, heparin and heparan sulfate, hep and HS)和硫酸角质素(keratan sulfate, KS) [<xref ref-type="bibr" rid="hanspub.24925-ref6">6</xref>] 。</p><p>母乳中GAGs的含量(416.2 mg/L)约为牛乳中的7倍(60.2 mg/L)，且主要成分不同：母乳GAGs的主要成分是硫酸软骨素(占总GAGs的55%)和硫酸乙酰肝素(42%)，与此相反，硫酸皮肤素占牛乳GAGs近40%，而肝素和硫酸软骨素分别约占30%和21% [<xref ref-type="bibr" rid="hanspub.24925-ref25">25</xref>] 。有实验表明，配方奶粉喂养的儿童GAGs利用率较低，硫酸软骨素和硫酸乙酰肝素的利用比母乳喂养的儿童低10~18倍 [<xref ref-type="bibr" rid="hanspub.24925-ref26">26</xref>] 。早产儿母乳中的GAGs含量为足月儿的3倍，两者GAGs成分基本相同。在分娩后的第四天，早产母乳和足月儿母乳中GAGs含量分别为9.3 g/L和3.8 g/L，而分娩后第30天，含量分别下降到4.3 g/L和0.4 g/L [<xref ref-type="bibr" rid="hanspub.24925-ref27">27</xref>] 。综上我们推测，母乳的利用度和可用性远高于以牛乳为主要成分的配方奶粉，同时早产母乳中高浓度的GAGs将对早产新生儿产生重要作用。综合国内外研究，我们将GAGs主要作用总结如下图2。</p><p>研究表明，同低聚糖作用机制类似，GAGs通过抵抗病原菌粘附以防止感染，如Coppa G V等 [<xref ref-type="bibr" rid="hanspub.24925-ref28">28</xref>] 的实验验证了母乳中GAGs可以在体外抑制大肠杆菌(E.coli 0119)和沙门氏菌(S.fyris)对人肠道细胞的粘附，其中S.fyris对Caco-2细胞和Int-407细胞的粘附性显著降低，提示我们母乳中的GAGs可能会成为母乳喂养的婴儿急性腹泻感染的重要防御因素之一。Newburg D S等 [<xref ref-type="bibr" rid="hanspub.24925-ref29">29</xref>] 通过实验证实，GAGs中的硫酸软骨素或硫酸软骨素样成分可抑制gp120与CD4<sup>+</sup>T淋巴细胞结合的能力，从而抑制艾滋病病毒感染，并推测GAGs可以限制艾滋病病毒母婴垂直传播的速度。此外，GAGs还可以发挥益生元、抗炎剂、抗氧化剂 [<xref ref-type="bibr" rid="hanspub.24925-ref30">30</xref>] 、膳食纤维等诸多功能。由此可见，母乳中的GAGs对新生儿作用显著，但国内外针对GAGs的研究相对较少并集中于硫酸软骨素。因此，不同浓度的GAGs及GAGs中具体成分的生理作用、作用机制、代谢转归和对新生儿健康的影响等亟待更深入的研究。</p></sec><sec id="s4_3"><title>2.3. 糖蛋白</title><p>母乳中的糖蛋白主要包括乳铁蛋白(LF)、免疫球蛋白(Ig)、黏蛋白(mucin)、胆盐刺激脂酶、髓过氧化物酶、丁香脂、乳链球蛋白、黄嘌呤脱氢酶/氧化酶、酪蛋白、瘦蛋白、脂联素和α-乳清蛋白等 [<xref ref-type="bibr" rid="hanspub.24925-ref6">6</xref>] 。母乳</p><p>图2. 母乳GAGs代谢转归及生物学功能 [<xref ref-type="bibr" rid="hanspub.24925-ref31">31</xref>]</p><p>中主要的糖蛋白可以防止微生物感染和体外过度免疫反应，这表明母乳糖蛋白是母亲保护婴儿尤其是早产儿免受病原菌感染的重要组分。</p><sec id="s4_3_1"><title>2.3.1. 乳铁蛋白</title><p>近年来科学研究表明，乳铁蛋白在防治胃肠道疾病方面具有重要意义。乳铁蛋白是来自转铁蛋白家族的糖蛋白，其在初乳中浓度 &gt; 7.0 g/L，在成熟母乳浓度约为1~2 g/L，而牛乳铁蛋白(bLF)的浓度在牛初乳中 &gt; 1.5 g/L，在泌乳期中降低至约20~200 mg/L；此外，母乳中乳铁蛋白饱和度(5%~8%)低于牛乳(15%~20%)，而铁饱和度越低，螯合铁的能力越强，由此可见相比牛乳，母乳乳铁蛋白发挥着更强大的作用 [<xref ref-type="bibr" rid="hanspub.24925-ref32">32</xref>] 。</p><p>乳铁蛋白具有免疫调节、促进细胞增殖、调节肠道菌群、抗微生物和抗炎等功能。Hu W [<xref ref-type="bibr" rid="hanspub.24925-ref33">33</xref>] 等通过用含有重组母乳乳铁蛋白(rhLF)的转基因奶喂养断奶期的猪仔实验，得出rhLF组猪仔肠道中沙门氏菌和大肠杆菌等致病菌数量减少，双歧杆菌和乳酸杆菌等有益菌数量增加，且其肠道微生物群呈现出较高的多样性和复杂性，证明乳铁蛋白可以调节肠道菌群。乳铁蛋白的抗微生物功能与其从生物体液中螯合铁和/或破坏微生物膜的能力有关：其抗菌能力在于与细菌表面受体相互作用，如Bessler H C等 [<xref ref-type="bibr" rid="hanspub.24925-ref34">34</xref>] 的数据表明，母乳中乳铁蛋白可以抑制鼠伤寒沙门氏菌对HeLa细胞的粘附和侵袭，这是抗鼠伤寒沙门氏菌感染的初始步骤；此外，乳铁蛋白被消化后产生肽环lactoferricin B，对革兰阳性和革兰阴性细菌病原体具有强大的抗菌活性。乳铁蛋白也被证实与抑制丙型肝炎病毒、单纯疱疹病毒、巨细胞病毒、HIV病毒、脊髓灰质炎病毒、腺病毒等相关 [<xref ref-type="bibr" rid="hanspub.24925-ref35">35</xref>] 。其抗炎作用与其阻断白细胞核因子NF-Kappa B的转录能力、减少促炎因子的释放有关，如Bertuccini L [<xref ref-type="bibr" rid="hanspub.24925-ref36">36</xref>] 等证明依赖甘露糖的乳铁蛋白通过与细菌I型菌毛结合，抑制侵袭性大肠杆菌株LF82粘附于肠上皮细胞，同时TNF-α、IL-8、IL-6等促炎因子被明显抑制。</p></sec><sec id="s4_3_2"><title>2.3.2. 免疫球蛋白</title><p>母乳中的免疫球蛋白主要是IgA、IgG、IgM，IgG是唯一能够通过母体通过胎盘转移到胎儿体内的免疫球蛋白，而IgA，IgM只能从初乳中摄入。免疫球蛋白对新生儿抗菌、抗病毒、抗毒素具有重要意义，在抗感染免疫中发挥重要作用。</p><p>近年来，国内外对母乳中糖蛋白的研究以SIgA为主。母乳中的SIgA可以通过调节肠道共生细菌的组成和活性，促进健康菌群的发展：如Stefano L M等 [<xref ref-type="bibr" rid="hanspub.24925-ref37">37</xref>] 的研究发现，母乳喂养的野生型小鼠肠道菌群中乳酸杆菌富集，喂食缺乏SIgA的母乳小鼠肠道菌群中条件致病菌增加，而在喂食补充了SIgA的母乳后条件致病菌消失而益生菌短暂出现。这证实了母乳中的SIgA在幼鼠对抗致病菌的过程中发挥着至关重要的作用。Rogier E W等 [<xref ref-type="bibr" rid="hanspub.24925-ref38">38</xref>] 通过实验证明，新生儿早期摄入母乳SIgA可阻止机会性致病菌如人苍白杆菌(Ochrobactrum anthropi)破坏肠上皮屏障并从肠道转运至肠系膜淋巴结的过程；持续喂养小鼠一段时间至断奶年龄后，摄入母乳SIgA的小鼠与未摄入SIgA的小鼠具有显著不同的肠道微生物群，如缺乏SIgA喂养的裸鼠变形菌门的丛毛单胞菌科显著增加，这与伴憩室炎的IBD患者肠道菌群变化一致；当小鼠达到成年时，这些差异被放大。另一方面，SIgA影响肠上皮细胞促炎基因和抑炎基因的表达平衡，从而发挥长期抗炎作用。Rogier E W [<xref ref-type="bibr" rid="hanspub.24925-ref39">39</xref>] 等的进一步研究发现，摄入SIgA和未摄入SIgA的成年小鼠肠上皮细胞基因表达不同，包括与人类肠道炎性疾病相关的基因：一些受SIgA调控的基因与增加IBD风险的人类基因(如人类1号染色体上的PIGR基因)同源，该基因表达的下调可能会通过降低早期母乳中SIgA的浓度加重IBD，并终生减少内源性SIgA在肠道的主动运输。上述结果证实了母乳喂养可以减少炎症性肠病(IBD)发生的假说，也表明如果婴儿缺乏母乳SIgA，可能通过改变肠道微生物和上皮细胞基因表达导致肠道炎症的易感性增加。</p></sec><sec id="s4_3_3"><title>2.3.3. 黏蛋白</title><p>黏蛋白是细胞外基质的主要成分，其作用包括防止上皮细胞被病原体感染，调节细胞信号传导和转录等 [<xref ref-type="bibr" rid="hanspub.24925-ref40">40</xref>] 。人类母乳中主要的黏蛋白为mucin 1和mucin 4，可与微生物相互作用。Mthembu Y等 [<xref ref-type="bibr" rid="hanspub.24925-ref41">41</xref>] 发现，在150 mg/L的典型母乳浓度下，mucin 1和mucin 4以剂量依赖的方式抑制血清型鼠伤寒沙门氏菌(SL1344)入侵人肠上皮细胞(FHs 74 Int和Caco-2)，从而证明黏蛋白可作为由沙门氏菌和相关病原体引起的婴儿疾病的新型口服预防和治疗剂。此外，纯化的mucin 1和mucin 4被证实可在体外抑制HIV-1型病毒 [<xref ref-type="bibr" rid="hanspub.24925-ref42">42</xref>] 。既往研究表明，母乳中的低聚糖、糖蛋白等糖成分可被树突细胞或特定组织细胞的C-型凝集素所识别，从而在免疫调节和免疫稳态中发挥重要功能，而DC-SIGN是一种具有显著特征的C-型凝集素。研究表明，母乳中的mucin 1存在Lewis x型低聚糖，是与DC-SIGN的凝集素结构域相结合的主要糖蛋白，从而抑制病原菌与其婴儿宿主细胞表面糖受体结合。值得强调的是，DC-SIGN表达于整个新生儿胃肠道，而有能力与DC-SIGN结合的糖蛋白仅见于母乳 [<xref ref-type="bibr" rid="hanspub.24925-ref43">43</xref>] 。由此可见，黏蛋白可在婴儿抵御入侵病原体的先天免疫中发挥作用。但由于黏蛋白分子量大、疏水性强，使其分离提纯十分困难，目前国内外相关研究均围绕mucin 1, 4开展，相信随着科学技术的发展，其他黏蛋白的功能将逐渐明确。</p></sec></sec><sec id="s4_4"><title>2.4. 其他</title><p>除上述作用外，Karav S等 [<xref ref-type="bibr" rid="hanspub.24925-ref44">44</xref>] 的最新实验结果显示，内-β-N-乙酰氨基葡萄糖苷酶(EndoBI-1)可以水解母乳糖蛋白释放出N-聚糖(N-glycans)，从而作为婴儿双歧杆菌(B. infantis)选择性生长的唯一碳源，而该促进生长的作用强于糖蛋白本身。因此，N-聚糖可以作为新型益生元底物发挥类似于母乳低聚糖的作用。该结果为研究母乳中糖蛋白的功能和作用机制提供了新的研究方向。</p><p>乳糖是人乳中最主要的碳水化合物，可以被β-半乳糖苷酶水解为单糖、半乳糖和葡萄糖，主要为婴儿提供能量，有关其对肠道菌群的调节作用鲜见报道。Okada K等人通过实验发现，喂养早产大鼠过量母乳后，大鼠体内炎症因子表达显著增加、肠道炎症甚至坏死性小肠结肠炎的发病率升高，而乳糖作为一种渗透压调节剂，其浓度可反映母乳的分泌量，因此当喂养早产婴儿时，母乳中的乳糖水平需受到密切关注 [<xref ref-type="bibr" rid="hanspub.24925-ref45">45</xref>] 。</p><p>目前针对母乳糖脂的研究证实，神经节苷脂可以与志贺毒素等细菌毒素结合 [<xref ref-type="bibr" rid="hanspub.24925-ref46">46</xref>] ，从而在婴儿肠道内发挥抗感染作用。但母乳糖脂是否具有临床意义有待深入研究。</p></sec></sec><sec id="s5"><title>3. 总结与展望</title><p>近年来，围绕母婴微生态展开的研究无疑是各国科学家关注的热点。随着以PCR-DGGE、高通量测序技术为代表的分子生物学技术的普及，母乳中糖成分对新生儿肠道微生物的影响逐渐为世人所知：一方面，母乳中的糖成分直接作用于新生儿肠道菌群，通过益生作用促进有益菌的定植和成熟，通过抑制病原菌粘附阻止有害菌的定植，降低感染、炎症等发生的可能；另一方面，肠道菌群及其分泌的酶类物质可以分解代谢母乳中的糖成分产生小分子有机酸，发挥参与肠道形成、抑制炎症反应、促进肠黏膜稳态平衡等作用。由此可见，新生儿肠道微生物在母乳影响新生儿健康中起到了不可替代的桥梁作用。因此，提倡母乳喂养、改善配方奶粉的成分及含量，甚至通过母乳成分预测、预防、治疗某些临床疾病应是母婴微生态研究的目标。目前，对母乳低聚糖的研究深入而广泛并取得显著成果，但针对母乳中葡萄糖胺聚糖、糖蛋白等成分对新生儿肠道微生物的调节作用研究甚少，有待于进一步探索，我们的研究将围绕这一方向展开。</p></sec><sec id="s6"><title>文章引用</title><p>胡雨奇,许尧,张利龙,刘翘楚,金 祺,孙露丹,李 明. 母乳糖成分对新生儿肠道微生物的调节作用研究 Review on the Regulation Function of Human Milk Glycans on Neonatal Gut Microbiota[J]. 食品与营养科学, 2018, 07(02): 81-90. https://doi.org/10.12677/HJFNS.2018.72010</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24925-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tremaroli, V. and Bäckhed, F. (2012) Functional Interactions between the Gut Microbiota and Host Metabolism. Nature, 489, 242-249.</mixed-citation></ref><ref id="hanspub.24925-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bäckhed, F., Roswall, J., Peng, Y., et al. (2015) Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell Host &amp; Microbe, 17, 690. &lt;br&gt;https://doi.org/10.1016/j.chom.2015.04.004</mixed-citation></ref><ref id="hanspub.24925-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pannaraj, P.S., Li, F., Cerini, C., et al. (2017) Association between Breast Milk Bacterial Communities and Establishment and Development of the Infant Gut Microbiome. JAMA Pediatrics, 171, 647.  
&lt;br&gt;https://doi.org/10.1001/jamapediatrics.2017.0378</mixed-citation></ref><ref id="hanspub.24925-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nieuwdorp, M., Gilijamse, P.W., Pai, N., et al. (2014) Role of the Microbiome in Energy Regulation and Metabolism. Gastroenterology, 146, 1525-1533. &lt;br&gt;https://doi.org/10.1053/j.gastro.2014.02.008</mixed-citation></ref><ref id="hanspub.24925-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ballard, O. and Morrow, A.L. (2013) Human Milk Composition: Nutrients and Bioactive Factors. Pediatric Clinics of North America, 60, 49-74. &lt;br&gt;https://doi.org/10.1016/j.pcl.2012.10.002</mixed-citation></ref><ref id="hanspub.24925-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Newburg, D.S. (2013) Glycobiology of Human Milk. Biochemistry Biokhimiia, 78, 771.  
&lt;br&gt;https://doi.org/10.1134/S0006297913070092</mixed-citation></ref><ref id="hanspub.24925-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Newburg, D.S., Ruizpalacios, G.M. and Morrow, A.L. (2005) Human Milk Glycans Protect Infants against Enteric Pathogens. Annual Review of Nutrition, 25, 37. &lt;br&gt;https://doi.org/10.1146/annurev.nutr.25.050304.092553</mixed-citation></ref><ref id="hanspub.24925-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Newburg, D.S., Tanritanir, A.C. and Chakrabarti, S. (2016) Lactodifucotetraose, a Human Milk Oligosaccharide, Attenuates Platelet Function and Inflammatory Cytokine Release. Journal of Thrombosis &amp; Thrombolysis, 42, 46.  
&lt;br&gt;https://doi.org/10.1007/s11239-015-1331-2</mixed-citation></ref><ref id="hanspub.24925-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lin, A.E., Autran, C.A., Szyszka, A., et al. (2017) Human Milk Oligosaccharides Inhibit Growth of Group B Streptococcus. Journal of Biological Chemistry, 292.</mixed-citation></ref><ref id="hanspub.24925-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zivkovic, A.M. and Klaenhammer, T.R. (2011) Human Milk Glycobiome and Its Impact on the Infant Gastrointestinal Microbiota. Proceedings of the National Academy of Sciences of the United States of America, 108, 4653-4658.  
&lt;br&gt;https://doi.org/10.1073/pnas.1000083107</mixed-citation></ref><ref id="hanspub.24925-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Z.T., Chen, C., Kling, D.E., et al. (2013) The Principal Fucosylated Oligosaccharides of Human Milk Exhibit Prebiotic Properties on Cultured Infant Microbiota. Glycobiology, 23, 169-177. &lt;br&gt;https://doi.org/10.1093/glycob/cws138</mixed-citation></ref><ref id="hanspub.24925-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Matsuki, T., Yahagi, K., Mori, H., et al. (2016) A Key Genetic Factor for Fucosyllactose Utilization Affects Infant Gut Microbiota Development. Nature Communications, 7, 11939. &lt;br&gt;https://doi.org/10.1038/ncomms11939</mixed-citation></ref><ref id="hanspub.24925-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Garrido, D., Ruiz-Moyano, S., Kirmiz, N., et al. (2016) A Novel Gene Cluster Allows Preferential Utilization of Fucosylated Milk Oligosaccharides in Bifidobacterium longum Subsp. Longum SC596. Scientific Reports, 6, 35045.  
&lt;br&gt;https://doi.org/10.1038/srep35045</mixed-citation></ref><ref id="hanspub.24925-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Williams, J.E., Price, W.J., Shafii, B., et al. (2017) Relationships among Microbial Communities, Maternal Cells, Oligosaccharides, and Macronutrients in Human Milk. Journal of Human Lactation, 6, 540-551.  
&lt;br&gt;https://doi.org/10.1177/0890334417709433</mixed-citation></ref><ref id="hanspub.24925-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Underwood, M.A., Gaerlan, S., Leoz, M.L.A.D., et al. (2015) Human Milk Oligosaccharides in Premature Infants: Absorption, Excretion and Influence on the Intestinal Microbiota. Pediatric Research, 78, 670-677.  
&lt;br&gt;https://doi.org/10.1038/pr.2015.162</mixed-citation></ref><ref id="hanspub.24925-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ruizpalacios, G.M., Cervantes, L.E., Ramos, P., et al. (2003) Campylobacter Jejuni Binds Intestinal H(O) Antigen (Fucα1, 2Galβ1, 4GlcNAc), and Fucosyloligosaccharides of Human Milk Inhibit Its Binding and Infection. Journal of Biological Chemistry, 278, 14112. &lt;br&gt;https://doi.org/10.1074/jbc.M207744200</mixed-citation></ref><ref id="hanspub.24925-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cilieborg, M., Sangild, P.T., Jensen, M.L., et al. (2017) a-1,2-Fucosyllactose Does Not Improve Intestinal Function or Prevent Escherichia coli F18 Diarrhea in Newborn Pigs. Journal of Pediatric Gastroenterology &amp; Nutrition, 64, 310.  
&lt;br&gt;https://doi.org/10.1097/MPG.0000000000001276</mixed-citation></ref><ref id="hanspub.24925-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nanda, N., Di, M. and Newburg, D.S. (2013) Glucocorticoids and Microbiota Regulate Ontogeny of Intestinal Fucosyltransferase 2 Requisite for Gut Homeostasis. Glycobiology, 23, 1131-1141. &lt;br&gt;https://doi.org/10.1093/glycob/cwt050</mixed-citation></ref><ref id="hanspub.24925-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Autran, C.A., Kellman, B.P., Kim, J.H., et al. (2017) Human Milk Oligosaccharide Composition Predicts Risk of Necrotising Enterocolitis in Preterm Infants. Gut.</mixed-citation></ref><ref id="hanspub.24925-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, C.J., Embleton, N.D., Marrs, E.C.L., et al. (2016) Temporal Bacterial and Metabolic Development of the Preterm Gut Reveals Specific Signatures in Health and Disease. Microbiome, 4, 67.  
&lt;br&gt;https://doi.org/10.1186/s40168-016-0216-8</mixed-citation></ref><ref id="hanspub.24925-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Autran, C.A., Schoterman, M.H., Jantscher-Krenn, E., et al. (2016) Sialylated Galacto-Oligosaccharides and 2’-Fucosyllactose Reduce Necrotising Enterocolitis in Neonatal Rats. British Journal of Nutrition, 116, 294-299.  
&lt;br&gt;https://doi.org/10.1017/S0007114516002038</mixed-citation></ref><ref id="hanspub.24925-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Faust, K., Sathirapongsasuti, J.F., Izard, J., et al. (2012) Microbial Co-Occurrence Relationships in the Human Microbiome. PLOS Computational Biology, 8, e1002606. &lt;br&gt;https://doi.org/10.1371/journal.pcbi.1002606</mixed-citation></ref><ref id="hanspub.24925-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Mezoff, E., Hawkins, J., Ollberding, N.J., et al. (2016) The Human Milk Oligosaccharide 2’-Fucosyllactose Augments the Adaptive Response to Extensive Intestinal Resection. American Journal of Physiology Gastrointestinal &amp; Liver Physiology, 310, G427. &lt;br&gt;https://doi.org/10.1152/ajpgi.00305.2015</mixed-citation></ref><ref id="hanspub.24925-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Charbonneau, M., O’Donnell, D., Blanton, L.V., et al. (2016) Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition. Cell, 164, 859. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.01.024</mixed-citation></ref><ref id="hanspub.24925-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Coppa, G.V., Gabrielli, O., Buzzega, D., et al. (2011) Composition and Structure Elucidation of Human Milk Glycosaminoglycans. Glycobiology, 21, 295-303. &lt;br&gt;https://doi.org/10.1093/glycob/cwq164</mixed-citation></ref><ref id="hanspub.24925-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Maccari, F., Mantovani, V., Gabrielli, O., et al. (2016) Metabolic Fate of Milk Glycosaminoglycans in Breastfed and Formula Fed Newborns. Glycoconjugate Journal, 33, 181-188. &lt;br&gt;https://doi.org/10.1007/s10719-016-9655-5</mixed-citation></ref><ref id="hanspub.24925-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Coppa, G.V., Gabrielli, O., Zampini, L., et al. (2012) Glycosaminoglycan Content in Term and Preterm Milk during the First Month of Lactation. Neonatology, 101, 74-76. &lt;br&gt;https://doi.org/10.1159/000330848</mixed-citation></ref><ref id="hanspub.24925-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Coppa, G.V., Facinelli, B., Magi, G., et al. (2015) Human Milk Glycosaminoglycans Inhibit in Vitro the Adhesion of Escherichia coli and Salmonella fyris to Human Intestinal Cells. Pediatric Research, 79, 603.  
&lt;br&gt;https://doi.org/10.1038/pr.2015.262</mixed-citation></ref><ref id="hanspub.24925-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Newburg, D.S., Linhardt, R., Ampofo, S.A., et al. (1995) Human Milk Glycosaminoglycans Inhibit HIV Glycoprotein gp120 Binding to Its Host Cell CD4 Receptor. Journal of Nutrition, 125, 419.</mixed-citation></ref><ref id="hanspub.24925-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Egea, J., Garcia, A.G., Verges, J., et al. (2010) Antioxidant, Antiinflammatory and Neuroprotective Actions of Chondroitin Sulfate and Proteoglycans. Osteoarthritis &amp; Cartilage, 18, S24.</mixed-citation></ref><ref id="hanspub.24925-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Coppa, G.V., Gabrielli, O., Bertino, E., et al. (2013) Human Milk Glycosaminoglycans: The State of the Art and Future Perspectives. Italian Journal of Pediatrics, 39, 2. &lt;br&gt;https://doi.org/10.1186/1824-7288-39-2</mixed-citation></ref><ref id="hanspub.24925-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Queiroz, V. and Assis, A.M. (2013) Protective Effect of Human Lactoferrin in the Gastrointestinal Tract. Revista Paulista De Pediatria Orgao Oficial Da Sociedade De Pediatria De Sao Paulo, 31, 90.  
&lt;br&gt;https://doi.org/10.1590/S0103-05822013000100015</mixed-citation></ref><ref id="hanspub.24925-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Hu, W., Zhao, J., Wang, J., et al. (2012) Transgenic Milk Containing Recombinant Human Lactoferrin Modulates the Intestinal Flora in Piglets. Biochemistry and Cell Biology, 90, 485. &lt;br&gt;https://doi.org/10.1139/o2012-003</mixed-citation></ref><ref id="hanspub.24925-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Bessler, H.C., de Oliveira, I.R. and Giugliano, L.G. (2006) Human Milk Glycoproteins Inhibit the Adherence of Salmonella typhimurium to HeLa Cells. Microbiology &amp; Immunology, 50, 877-882.  
&lt;br&gt;https://doi.org/10.1111/j.1348-0421.2006.tb03863.x</mixed-citation></ref><ref id="hanspub.24925-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Redwan, E.M., Uversky, V.N., Elfakharany, E.M., et al. (2014) Potential Lactoferrin Activity against Pathogenic Viruses. Comptes Rendus Biologies, 337, 581. &lt;br&gt;https://doi.org/10.1016/j.crvi.2014.08.003</mixed-citation></ref><ref id="hanspub.24925-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Bertuccini, L., Costanzo, M., Iosi, F., et al. (2014) Lactoferrin Prevents Invasion and Inflammatory Response Following E. Coli Strain LF82 Infection in Experimental Model of Crohn’s Disease. Digestive &amp; Liver Disease Official Journal of the Italian Society of Gastroenterology &amp; the Italian Association for the Study of the Liver, 46, 496-504.  
&lt;br&gt;https://doi.org/10.1016/j.dld.2014.02.009</mixed-citation></ref><ref id="hanspub.24925-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Stefano, L.M., Federica, D.C., Pamela, V., et al. (2016) Monitoring Perinatal Gut Microbiota in Mouse Models by Mass Spectrometry Approaches: Parental Genetic Background and Breastfeeding Effects. Frontiers in Microbiology, 7, 1523.</mixed-citation></ref><ref id="hanspub.24925-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Rogier, E.W., Frantz, A.L., Bruno, M.E., et al. (2014) Secretory Antibodies in Breast Milk Promote Long-Term Intestinal Homeostasis by Regulating the Gut Microbiota and Host Gene Expression. Proceedings of the National Academy of Sciences of the United States of America, 111, 3074. &lt;br&gt;https://doi.org/10.1073/pnas.1315792111</mixed-citation></ref><ref id="hanspub.24925-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Rogier, E.W., Frantz, A.L., Bruno, M.E., et al. (2014) Lessons from Mother: Long-Term Impact of Antibodies in Breast Milk on the Gut Microbiota and Intestinal Immune System of Breastfed Offspring. Gut Microbes, 5, 663-668.  
&lt;br&gt;https://doi.org/10.4161/19490976.2014.969984</mixed-citation></ref><ref id="hanspub.24925-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Hattrup, C. and Gendler, S.J. (2008) Structure and Function of the Cell Surface (Tethered) Mucins. Annual Review of Physiology, 70, 431. &lt;br&gt;https://doi.org/10.1146/annurev.physiol.70.113006.100659</mixed-citation></ref><ref id="hanspub.24925-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Mthembu, Y., Lotz, Z., Tyler, M., et al. (2014) Purified Human Breast Milk MUC1 and MUC4 Inhibit Human Immunodeficiency Virus. Neonatology, 105, 211-217. &lt;br&gt;https://doi.org/10.1159/000357201</mixed-citation></ref><ref id="hanspub.24925-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Yu, Z., Chen, C., et al. (2012) Human Milk Mucin 1 and Mucin 4 Inhibit Salmonella enterica Serovar Typhimurium Invasion of Human Intestinal Epithelial Cells in Vitro. Journal of Nutrition, 142, 1504-1509.  
&lt;br&gt;https://doi.org/10.3945/jn.111.155614</mixed-citation></ref><ref id="hanspub.24925-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Koning, N., Kessen, S.F., Jp, V.D.V., et al. (2015) Human Milk Blocks DC-SIGN-Pathogen Interaction via MUC1. Frontiers in Immunology, 6, 112. &lt;br&gt;https://doi.org/10.3389/fimmu.2015.00112</mixed-citation></ref><ref id="hanspub.24925-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Karav, S., Le, P.A., Jm, L.N.D.M.B., et al. (2016) Oligosaccharides Released from Milk Glycoproteins Are Selective Growth Substrates for Infant-Associated Bifidobacteria. Applied and Environmental Microbiology, 82, 3622.  
&lt;br&gt;https://doi.org/10.1128/AEM.00547-16</mixed-citation></ref><ref id="hanspub.24925-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Okada, K., Fujii, T., Ohtsuka, Y., et al. (2010) Overfeeding Can Cause NEC-Like Enterocolitis in Premature Rat Pups. Neonatology, 97, 218-224. &lt;br&gt;https://doi.org/10.1159/000253150</mixed-citation></ref><ref id="hanspub.24925-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Giuffrida, F., Elmelegy, I.M., Thakkar, S.K., et al. (2014) Longitudinal Evolution of the Concentration of Gangliosides GM3 and GD3 in Human Milk. Lipids, 49, 997-1004. &lt;br&gt;https://doi.org/10.1007/s11745-014-3943-2</mixed-citation></ref></ref-list></back></article>